Profile data is unavailable for this security.
About the company
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
- Revenue in USD (TTM)0.00
- Net income in USD-23.56m
- Incorporated2014
- Employees18.00
- LocationImmix Biopharma Inc11400 West Olympic Blvd., Suite 200LOS ANGELES 90064United StatesUSA
- Phone+1 (310) 651-8041
- Websitehttps://immixbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Candel Therapeutics Inc | 0.00 | -22.76m | 290.41m | 38.00 | -- | 3.62 | -- | -- | -0.5591 | -0.5591 | 0.00 | 1.46 | 0.00 | -- | -- | 0.00 | -39.54 | -51.34 | -51.19 | -60.61 | -- | -- | -- | -44,190.40 | -- | -- | 0.0609 | -- | -- | -- | -45.44 | -- | -36.83 | -- |
| Immuneering Corp | 0.00 | -62.50m | 291.86m | 54.00 | -- | 1.26 | -- | -- | -1.78 | -1.78 | 0.00 | 3.59 | 0.00 | -- | -- | 0.00 | -40.37 | -46.52 | -42.64 | -49.48 | -- | -- | -- | -4,578.95 | -- | -- | 0.00 | -- | -- | -- | -14.15 | -- | 32.83 | -- |
| Amarin Corporation PLC | 226.73m | -86.19m | 292.97m | 275.00 | -- | 0.0319 | -- | 1.29 | -76.48 | -76.48 | 37.99 | 441.28 | 0.3215 | 0.4998 | 1.89 | 824,487.30 | -12.22 | -5.67 | -16.79 | -8.23 | 54.96 | 72.68 | -38.01 | -12.24 | 2.43 | -- | 0.00 | -- | -25.51 | -11.86 | -39.03 | -- | -- | -- |
| Armata Pharmaceuticals Inc | 5.05m | -46.90m | 294.17m | 60.00 | -- | -- | -- | 58.20 | -1.30 | -1.30 | 0.1396 | -2.64 | 0.0538 | -- | 3.39 | 84,233.34 | -49.96 | -47.36 | -- | -60.79 | -- | -- | -928.00 | -829.99 | -- | -2.12 | 2.88 | -- | 14.24 | -- | 72.60 | -- | 53.02 | -- |
| PepGen Inc | 0.00 | -93.56m | 294.93m | 81.00 | -- | 1.81 | -- | -- | -2.84 | -2.84 | 0.00 | 2.37 | 0.00 | -- | -- | 0.00 | -51.93 | -45.06 | -56.56 | -49.76 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.44 | -- | 76.52 | -- |
| Aldeyra Therapeutics Inc | 0.00 | -43.19m | 306.23m | 9.00 | -- | 6.22 | -- | -- | -0.7217 | -0.7217 | 0.00 | 0.8185 | 0.00 | -- | -- | 0.00 | -44.27 | -34.06 | -57.79 | -38.07 | -- | -- | -- | -- | -- | -- | 0.2359 | -- | -- | -- | -48.77 | -- | -- | -- |
| Foghorn Therapeutics Inc | 24.52m | -72.12m | 306.34m | 112.00 | -- | -- | -- | 12.49 | -1.15 | -1.15 | 0.3896 | -1.59 | 0.0955 | -- | -- | 218,910.70 | -28.10 | -28.66 | -38.84 | -33.19 | -- | -- | -294.16 | -596.97 | -- | -- | -- | -- | -33.83 | -- | 11.99 | -- | -1.32 | -- |
| Immix Biopharma Inc | 0.00 | -23.56m | 310.31m | 18.00 | -- | 23.78 | -- | -- | -0.7742 | -0.7742 | 0.00 | 0.2502 | 0.00 | -- | -- | 0.00 | -104.21 | -108.46 | -169.47 | -146.18 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.11 | -- | 176.33 | -- |
| CytoDyn Inc | 0.00 | -40.35m | 312.52m | 13.00 | -- | -- | -- | -- | -0.0322 | -0.0322 | 0.00 | -0.0946 | 0.00 | -- | -- | 0.00 | -229.87 | -225.45 | -- | -- | -- | -- | -- | -184,742.10 | -- | -6.09 | -- | -- | -- | -- | 104.41 | -- | -- | -- |
| Atea Pharmaceuticals Inc | 0.00 | -147.03m | 314.07m | 56.00 | -- | 0.9946 | -- | -- | -1.78 | -1.78 | 0.00 | 4.04 | 0.00 | -- | -- | 0.00 | -35.26 | -9.87 | -37.29 | -11.45 | -- | -- | -- | -77.50 | -- | -- | 0.00 | -- | -- | -- | -23.85 | -- | -- | -- |
| Climb Bio Inc | 0.00 | -50.75m | 317.06m | 17.00 | -- | 1.79 | -- | -- | -0.7507 | -0.7507 | 0.00 | 2.60 | 0.00 | -- | -- | 0.00 | -25.09 | -39.53 | -25.62 | -41.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -110.42 | -- | -- | -- |
| Neumora Therapeutics Inc | 0.00 | -236.30m | 323.00m | 95.00 | -- | 2.40 | -- | -- | -1.46 | -1.46 | 0.00 | 0.8161 | 0.00 | -- | -- | 0.00 | -89.11 | -55.45 | -99.96 | -58.77 | -- | -- | -- | -- | -- | -- | 0.1289 | -- | -- | -- | -3.33 | -- | -- | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -240.91m | 324.67m | 299.00 | -- | 1.03 | -- | -- | -2.25 | -2.25 | 0.00 | 2.90 | 0.00 | -- | -- | 0.00 | -63.25 | -38.97 | -69.77 | -41.67 | -- | -- | -- | -- | -- | -- | 0.0635 | -- | -- | -- | -5.35 | -- | -24.10 | -- |
| Protara Therapeutics Inc | 0.00 | -52.90m | 335.60m | 28.00 | -- | 1.90 | -- | -- | -1.43 | -1.43 | 0.00 | 3.43 | 0.00 | -- | -- | 0.00 | -44.32 | -35.06 | -48.05 | -36.43 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -10.33 | -- | 31.54 | -- |
| Aura Biosciences Inc | 0.00 | -106.47m | 340.38m | 106.00 | -- | 2.15 | -- | -- | -1.93 | -1.93 | 0.00 | 2.49 | 0.00 | -- | -- | 0.00 | -53.86 | -36.26 | -58.85 | -38.42 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.76 | -- | -10.82 | -- |
| Anavex Life Sciences Corp | 0.00 | -46.38m | 340.42m | 34.00 | -- | 3.48 | -- | -- | -0.5439 | -0.5439 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -38.75 | -33.08 | -43.11 | -36.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.85 | -- | -- | -- |
Data as of Feb 06 2026. Currency figures normalised to Immix Biopharma Inc's reporting currency: US Dollar USD
5.09%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 956.74k | 1.82% |
| Bleichroeder LPas of 30 Sep 2025 | 850.00k | 1.61% |
| Geode Capital Management LLCas of 30 Sep 2025 | 187.48k | 0.36% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 129.74k | 0.25% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2025 | 119.08k | 0.23% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 98.96k | 0.19% |
| Citadel Securities LLCas of 30 Sep 2025 | 89.49k | 0.17% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 89.30k | 0.17% |
| Next Edge Capital Corp.as of 30 Jun 2024 | 85.00k | 0.16% |
| G1 Execution Services LLCas of 30 Sep 2025 | 74.50k | 0.14% |
More ▼
Data from 30 Jun 2024 - 31 Dec 2025Source: FactSet Research Systems Inc.
